Amit-Bar-Or
Amit Bar-Or, MD

Dr. Bar-Or recently joined the University of Pennsylvania (UPenn/CHOP) where he holds the Melissa and Paul Anderson Professorship of Neurology and Presidential Endowed Chair and serves as founder and Director of the Centre for Neuroinflammation and Experimental Therapeutics as well as Chief of the Division of Multiple Sclerosis and related disorders. He is former Professor in the Department of Neurology and Neurosurgery, and Associate Director of the Montreal Neurological Institute and Hospital, McGill University. His clinical focus is Multiple Sclerosis (MS) and related disorders in both adults and children. He runs a cellular and molecular Neuroimmunology lab that studies basic principles of immune regulation and immune-neural interaction, in the context of inflammation, injury and repair of the human central nervous system (CNS). Research themes are directed at understanding principles of immune regulation, elucidation of effector and regulatory mechanisms of distinct immune cell (principally T cell, B cell, and myeloid cell) subsets in CNS inflammatory disease; immune reconstitution, neuro-immune interactions. A particular effort relates to immune monitoring, designing and implementing mechanism of action and biological proof-of-principle studies of emerging therapies, and development of clinically meaningful biomarkers as part of advancing precision medicine in autoimmune and CNS-inflammatory diseases. Dr. Bar-Or is passionate about education and mentoring, having trained over 80 students at all levels, with emphasis on clinician-scientist trainees, all of whom have continued active and successful careers at the clinical-research interface. He has published over 200 peer-reviewed publications, led multiple national and international collaborative research initiatives and am considered a highly sought after speaker. Dr. Bar-Or was past President of the Canadian Network of MS Clinics (CNMSC) and past member of the Board of Directors of the Federation of Clinical Immunology Societies (FOCIS). He is President-Elect and long-standing Scientific Advisory Board member of the International Society of Neuroimmunology (ISNI) and serves on the Board of Directors of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and on the Steering Committee of the NIH Immune Tolerance Network (ITN).